Paracetamol 1% solution — Competitive Intelligence Brief

Paracetamol 1% solution (Paracetamol 1% solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic and antipyretic. Area: Pain Management.

phase 3 Analgesic and antipyretic Cyclooxygenase (COX), primarily central nervous system isoforms Pain Management Small molecule

Target snapshot

Paracetamol 1% solution (Paracetamol 1% solution) — Baxter Healthcare Corporation. Paracetamol inhibits prostaglandin synthesis in the central nervous system to reduce pain and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paracetamol 1% solution TARGET	Paracetamol 1% solution	Baxter Healthcare Corporation	phase 3	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
IV Acetaminophen	IV Acetaminophen	Mallinckrodt	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes
acetaminophen IV	acetaminophen IV	Nantes University Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes
acetaminophen, IV preparation	acetaminophen, IV preparation	The University of Texas Health Science Center at San Antonio	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Tylenol Pill	Tylenol Pill	Shanghai Zhongshan Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Acetaminophen (Ofirmev)	Acetaminophen (Ofirmev)	Brigham and Women's Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes (central nervous system)
IV Acetaminophen (Treatment A)	IV Acetaminophen (Treatment A)	Mallinckrodt	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic and antipyretic class)

1. Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · 2 drugs in this class
2. Mallinckrodt · 2 drugs in this class
3. The University of Texas Health Science Center, Houston · 2 drugs in this class
4. Hellenic Society of Hematology · 1 drug in this class
5. John van den Anker · 1 drug in this class
6. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
7. Maoxiang Group Jilin Pharmaceutical Co., Ltd. · 1 drug in this class
8. Merck Sharp & Dohme LLC · 1 drug in this class
9. Mount Sinai Hospital, Canada · 1 drug in this class
10. Nantes University Hospital · 1 drug in this class